Get started
Author

Ilona Bebenek

An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)
2020 · Amy M. Avila, Ilona Bebenek, et al. · Regulatory Toxicology and Pharmacology · 197
Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies
2023 · Amy M. Avila, Ilona Bebenek, et al. · Regulatory Toxicology and Pharmacology · 60
Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies
2022 · Vijay P. Kale, Ilona Bebenek, et al. · International Journal of Toxicology · 24
FDA/CDER/OND Experience With New Approach Methodologies (NAMs)
2025 · Jia Yao, Jackye Peretz, et al. · International Journal of Toxicology · 18
PDF
COVID-19 Therapeutics and Vaccines: A Race to Save Lives
2021 · Ilona Bebenek, Roy Bannister, et al. · Toxicological Sciences · 13
Drug Development 101: A Primer
2020 · Lorrene A. Buckley, Ilona Bebenek, et al. · International Journal of Toxicology · 11
PDF
Toxicology and Drug Development
2023 · Ilona Bebenek, Owen McMaster · Royal Society of Chemistry eBooks
Works count: 7
Citation count: 323
H-index: 6
I10-index: 6
Year
Topic
Type